Ibironke Oduyebo1, Michael Camilleri. 1. Division of Gastroenterology and Hepatology, Mayo Clinic, Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Rochester, Minnesota, USA.
Abstract
PURPOSE OF REVIEW: Our objective was to review advances in bile acids in health and disease published in the last 2 years. Bile acid diarrhea (BAD) is recognized as a common cause of chronic diarrhea, and its recognition has been facilitated by development of new screening tests. RECENT FINDINGS: Primary BAD can account for 30% of cases of chronic diarrhea. The mechanisms leading to BAD include inadequate feedback regulation by fibroblast growth factor 19 (FGF-19) from ileal enterocytes, abnormalities in synthesis or degradation of proteins involved in FGF-19 regulation in hepatocytes and variations as a function of the bile acid receptor, TGR5 (GPBAR1). SeHCAT is the most widely used test for diagnosis of BAD. There has been significant validation of fasting serum FGF-19 and 7 α-hydroxy-cholesten-3-one (C4), a surrogate measure of bile acid synthesis. Bile acid sequestrants are the primary treatments for BAD; the farnesoid X-receptor-FGF-19 pathway provides alternative therapeutic targets for BAD. Bile acid-stimulated intestinal mechanisms contribute to the beneficial effects of bariatric surgery on obesity, glycemic control and the treatment of recurrent Clostridium difficile infection. SUMMARY: Renewed interest in the role of bile acids is leading to novel management of diverse diseases besides BAD.
PURPOSE OF REVIEW: Our objective was to review advances in bile acids in health and disease published in the last 2 years. Bile acid diarrhea (BAD) is recognized as a common cause of chronic diarrhea, and its recognition has been facilitated by development of new screening tests. RECENT FINDINGS: Primary BAD can account for 30% of cases of chronic diarrhea. The mechanisms leading to BAD include inadequate feedback regulation by fibroblast growth factor 19 (FGF-19) from ileal enterocytes, abnormalities in synthesis or degradation of proteins involved in FGF-19 regulation in hepatocytes and variations as a function of the bile acid receptor, TGR5 (GPBAR1). SeHCAT is the most widely used test for diagnosis of BAD. There has been significant validation of fasting serum FGF-19 and 7 α-hydroxy-cholesten-3-one (C4), a surrogate measure of bile acid synthesis. Bile acid sequestrants are the primary treatments for BAD; the farnesoid X-receptor-FGF-19 pathway provides alternative therapeutic targets for BAD. Bile acid-stimulated intestinal mechanisms contribute to the beneficial effects of bariatric surgery on obesity, glycemic control and the treatment of recurrent Clostridium difficileinfection. SUMMARY: Renewed interest in the role of bile acids is leading to novel management of diverse diseases besides BAD.
Authors: Alexa R Weingarden; Chi Chen; Ningning Zhang; Carolyn T Graiziger; Peter I Dosa; Clifford J Steer; Megan K Shaughnessy; James R Johnson; Michael J Sadowsky; Alexander Khoruts Journal: J Clin Gastroenterol Date: 2016-09 Impact factor: 3.062
Authors: F Fernández-Bañares; M Rosinach; M Piqueras; A Ruiz-Cerulla; I Modolell; Y Zabana; J Guardiola; M Esteve Journal: Aliment Pharmacol Ther Date: 2015-04-10 Impact factor: 8.171
Authors: M Camilleri; A Acosta; I Busciglio; A Boldingh; R B Dyer; A R Zinsmeister; A Lueke; A Gray; L J Donato Journal: Aliment Pharmacol Ther Date: 2015-01-16 Impact factor: 8.171
Authors: Julian R F Walters; Ali M Tasleem; Omer S Omer; W Gordon Brydon; Tracy Dew; Carel W le Roux Journal: Clin Gastroenterol Hepatol Date: 2009-05-06 Impact factor: 11.382
Authors: Nelson Valentin; Michael Camilleri; Osama Altayar; Priya Vijayvargiya; Andres Acosta; Alfred D Nelson; M Hassan Murad Journal: Gut Date: 2015-09-07 Impact factor: 23.059
Authors: Michael Camilleri; Irene Busciglio; Andres Acosta; Andrea Shin; Paula Carlson; Duane Burton; Michael Ryks; Deborah Rhoten; Jesse Lamsam; Alan Lueke; Leslie J Donato; Alan R Zinsmeister Journal: Am J Gastroenterol Date: 2014-07-29 Impact factor: 10.864
Authors: Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne Journal: Gut Date: 2019-09-27 Impact factor: 23.059
Authors: Jessica M Lee; Jessica R Ong; Laurent Vergnes; Thomas Q de Aguiar Vallim; Jonathan Nolan; Rita M Cantor; Julian R F Walters; Karen Reue Journal: J Lipid Res Date: 2018-01-02 Impact factor: 5.922
Authors: Biki Gupta; Yunshan Liu; Daniel M Chopyk; Ravi P Rai; Chirayu Desai; Pradeep Kumar; Alton B Farris; Asma Nusrat; Charles A Parkos; Frank A Anania; Reben Raeman Journal: FASEB J Date: 2020-04-10 Impact factor: 5.191
Authors: Ivan Lyutakov; Francesco Ursini; Plamen Penchev; Giacomo Caio; Antonio Carroccio; Umberto Volta; Roberto De Giorgio Journal: BMC Gastroenterol Date: 2019-11-14 Impact factor: 3.067